FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287	7				
Estimated average	burden					
nours per response	e 0.	5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Kesponse	(8)																	
1. Name an Ahn Chan		f Reporting P	erson *	2. Issuer Name and Ticker of REXAHN PHARMACEU									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
	AHN PHA	(First) ARMACEU Y GROVE	(Middle) TICALS, ROAD, SUITE	3. Date of Earliest Transaction (Month/Day/Year) 12/14/2010							X_ Director X_ 10% Owner X_ Officer (give title below) Other (specify below) Chairman & CEO								
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
ROCKVI	LLE, MD	20850												roini inc	d by More than	One Reporting	i cison		
(City)	1	(State)	(Zip)		7	Гab	le I - N	Non-	Deri	vative S	ecur	ities A	Acqui	red, Dispo	sed of, or l	Beneficially	Owned		
1.Title of South				2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		tion	(A) or Disposed (Instr. 3, 4 and 5		sed of		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Ownership Form:		7. Nature of Indirect Beneficial Ownership		
						,	Cod	le	V	Amour	,	A) or (D)	Price				or Indir (I) (Instr. 4	ect (I	nstr. 4)
Common	Stock		12/14/2010				G		V	300,00	00 D)	\$ 0	10,220,0	000		D		
Common	Stock		12/14/2010				G		V	210,00	00 D)	\$ 0	10,010,0	000		D		
Common	Stock													500,000			I	b	pouse
Reminder: I	Report on a	separate line	for each class of secu	ırities b	eneficial	ly c	wned o	direc	tly o	r									
								c	cont	ained i	n thi	is for	m are	not req	uired to re	formation spond un itrol numb	less	SEC	02)
			Table II - I		ive Secui									ly Owned					
1. Title of	2.	3. Transactio	,	<u> </u>	1.					ate Exer			_ <u> </u>	itle and	8. Price of	9. Number	of 10.		11. Nature
Security (Instr. 3)	Conversion or Exercise Price of Derivative Security		/Year) Execution Da any (Month/Day/	(Fransactic Code Instr. 8)		of Deriva Securit Acquir (A) or Dispos of (D) (Instr. 4, and	tive ties red sed		Expiration the Day			te Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y Forn Deri Secu Dire or In	nership n of vative urity: ct (D) adirect er. 4)	(Instr. 4)
					Code	V	(A)		Date Exe	e rcisable		iration	Title	Amount or Number of Shares					

Reporting Owners

December Occurs Name / Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Ahn Chang Ho C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X	X	Chairman & CEO					

Signatures

/s/ TAE HEUM JEONG	12/16/2010
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 500,000 shares owned by the Reporting Person's wife, as to which the Reporting Person disclaims beneficial ownership.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.